SeraCare has expanded its AccuPlex line with the launch of the AccuSpan HCV RNA Linearity Panel. The eight-member panel has been qualified against World Health Organization standards and is made from serial dilutions of high-titer recombinant hepatitis C virus, genotype 1b, with established reactivity for HCV RNA, and one negative control. The panel can be used by researchers, diagnostics manufacturers, and clinical labs to develop, evaluate, and validate HCV molecular test methods. The panel is useful for monitoring HCV RNA recovery at defined intervals, identifying consistency over a linear range, assessing lot-to-lot variability of kits, performing linearity studies, or any time there may be deterioration in diagnostic assays, according to the firm. It uses SeraCare's proprietary AccuPlex technology, which packages recombinant viral material in a way that is stable, replication-deficient, non-infectious, and mimics a real patient sample throughout the diagnostic workflow.